1
|
Xu L, Zhang J, Yang H, Cao C, Fang R, Liu P, Luo S, Wang B, Zhang K, Wang L. Epistasis in neurotransmitter receptors linked to posttraumatic stress disorder and major depressive disorder comorbidity in traumatized Chinese. Front Psychiatry 2024; 15:1257911. [PMID: 38487579 PMCID: PMC10937445 DOI: 10.3389/fpsyt.2024.1257911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Accepted: 02/14/2024] [Indexed: 03/17/2024] Open
Abstract
Background Posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) comorbidity occurs through exposure to trauma with genetic susceptibility. Neuropeptide-Y (NPY) and dopamine are neurotransmitters associated with anxiety and stress-related psychiatry through receptors. We attempted to explore the genetic association between two neurotransmitter receptor systems and the PTSD-MDD comorbidity. Methods Four groups were identified using latent profile analysis (LPA) to examine the patterns of PTSD and MDD comorbidity among survivors exposed to earthquake-related trauma: low symptoms, predominantly depression, predominantly PTSD, and PTSD-MDD comorbidity. NPY2R (rs4425326), NPY5R (rs11724320), DRD2 (rs1079597), and DRD3 (rs6280) were genotyped from 1,140 Chinese participants exposed to earthquake-related trauma. Main, gene-environment interaction (G × E), and gene-gene interaction (G × G) effects for low symptoms, predominantly depression, and predominantly PTSD were tested using a multinomial logistic model with PTSD-MDD comorbidity as a reference. Results The results demonstrated that compared to PTSD-MDD comorbidity, epistasis (G × G) NPY2R-DRD2 (rs4425326 × rs1079597) affects low symptoms (β = -0.66, OR = 0.52 [95% CI: 0.32-0.84], p = 0.008, pperm = 0.008) and predominantly PTSD (β = -0.56, OR = 0.57 [95% CI: 0.34-0.97], p = 0.037, pperm = 0.039), while NPY2R-DRD3 (rs4425326 × rs6280) impacts low symptoms (β = 0.82, OR = 2.27 [95% CI: 1.26-4.10], p = 0.006, pperm = 0.005) and predominantly depression (β = 1.08, R = 2.95 [95% CI: 1.55-5.62], p = 0.001, pperm = 0.001). The two G × G effects are independent. Conclusion NPY and dopamine receptor genes are related to the genetic etiology of PTSD-MDD comorbidity, whose specific mechanisms can be studied at multiple levels.
Collapse
Affiliation(s)
- Ling Xu
- Laboratory for Traumatic Stress Studies and Center for Genetics and BioMedical Informatics Research, CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Jingyi Zhang
- Laboratory for Traumatic Stress Studies and Center for Genetics and BioMedical Informatics Research, CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Haibo Yang
- Academy of Psychology and Behavior, Tianjin Normal University, Tianjin, China
| | - Chengqi Cao
- Laboratory for Traumatic Stress Studies and Center for Genetics and BioMedical Informatics Research, CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Ruojiao Fang
- Laboratory for Traumatic Stress Studies and Center for Genetics and BioMedical Informatics Research, CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Ping Liu
- People’s Hospital of Deyang City, Deyang, Sichuan, China
| | - Shu Luo
- People’s Hospital of Deyang City, Deyang, Sichuan, China
| | - Binbin Wang
- Laboratory for Traumatic Stress Studies and Center for Genetics and BioMedical Informatics Research, CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Kunlin Zhang
- Laboratory for Traumatic Stress Studies and Center for Genetics and BioMedical Informatics Research, CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Li Wang
- Laboratory for Traumatic Stress Studies and Center for Genetics and BioMedical Informatics Research, CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
2
|
Han P, Jing X, Han S, Wang X, Li Q, Zhang Y, Yu P, Liu XA, Wu P, Chen H, Hou H, Hu Q. Pharmacokinetic differences in nicotine and nicotine salts mediate reinforcement-related behavior: an animal model study. Front Neurosci 2023; 17:1288102. [PMID: 38033549 PMCID: PMC10687399 DOI: 10.3389/fnins.2023.1288102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Accepted: 10/17/2023] [Indexed: 12/02/2023] Open
Abstract
Since their introduction in the United States and Europe in 2007, electronic cigarettes (E-Cigs) have become increasingly popular among smokers. Nicotine, a key component in both tobacco and e-cigarettes, can exist in two forms: nicotine-freebase (FBN) and nicotine salts (NS). While nicotine salt is becoming more popular in e-cigarettes, the effect of nicotine salts on reinforcement-related behaviors remains poorly understood. This study aimed to compare the reinforcing effects of nicotine and nicotine salts in animal models of drug self-administration and explore potential mechanisms that may contribute to these differences. The results demonstrated that three nicotine salts (nicotine benzoate, nicotine lactate, and nicotine tartrate) resulted in greater reinforcement-related behaviors in rats compared to nicotine-freebase. Moreover, withdrawal-induced anxiety symptoms were lower in the three nicotine salt groups than in the nicotine-freebase group. The study suggested that differences in the pharmacokinetics of nicotine-freebase and nicotine salts in vivo may explain the observed behavioral differences. Overall, this study provides valuable insights into the reinforcing effects of nicotine as well as potential differences between nicotine-freebase and nicotine salts.
Collapse
Affiliation(s)
- Pengfei Han
- Institute of Biomedical Engineering, College of Life Sciences, Qingdao University, Qingdao, China
- China National Tobacco Quality Supervision and Test Center, Zhengzhou, China
- Key Laboratory of Tobacco Biological Effects, Zhengzhou, China
- Beijing Life Science Academy, Beijing, China
- Key Laboratory of Tobacco Biological Effects and Biosynthesis, Beijing, China
| | - Xiaoyuan Jing
- Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
| | - Shulei Han
- China National Tobacco Quality Supervision and Test Center, Zhengzhou, China
- Key Laboratory of Tobacco Biological Effects, Zhengzhou, China
- Beijing Life Science Academy, Beijing, China
- Key Laboratory of Tobacco Biological Effects and Biosynthesis, Beijing, China
| | - Xinsheng Wang
- Institute of Biomedical Engineering, College of Life Sciences, Qingdao University, Qingdao, China
| | - Qiannan Li
- China National Tobacco Quality Supervision and Test Center, Zhengzhou, China
- Key Laboratory of Tobacco Biological Effects, Zhengzhou, China
- Beijing Life Science Academy, Beijing, China
- Key Laboratory of Tobacco Biological Effects and Biosynthesis, Beijing, China
| | - Yuan Zhang
- China National Tobacco Quality Supervision and Test Center, Zhengzhou, China
- Key Laboratory of Tobacco Biological Effects, Zhengzhou, China
- Beijing Life Science Academy, Beijing, China
- Key Laboratory of Tobacco Biological Effects and Biosynthesis, Beijing, China
| | - Pengpeng Yu
- China National Tobacco Quality Supervision and Test Center, Zhengzhou, China
- Key Laboratory of Tobacco Biological Effects, Zhengzhou, China
- Beijing Life Science Academy, Beijing, China
- Key Laboratory of Tobacco Biological Effects and Biosynthesis, Beijing, China
| | - Xin-an Liu
- Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
| | - Ping Wu
- National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Beijing, China
| | - Huan Chen
- China National Tobacco Quality Supervision and Test Center, Zhengzhou, China
- Key Laboratory of Tobacco Biological Effects, Zhengzhou, China
- Beijing Life Science Academy, Beijing, China
- Key Laboratory of Tobacco Biological Effects and Biosynthesis, Beijing, China
| | - Hongwei Hou
- China National Tobacco Quality Supervision and Test Center, Zhengzhou, China
- Key Laboratory of Tobacco Biological Effects, Zhengzhou, China
- Beijing Life Science Academy, Beijing, China
- Key Laboratory of Tobacco Biological Effects and Biosynthesis, Beijing, China
| | - Qingyuan Hu
- China National Tobacco Quality Supervision and Test Center, Zhengzhou, China
- Key Laboratory of Tobacco Biological Effects, Zhengzhou, China
- Beijing Life Science Academy, Beijing, China
- Key Laboratory of Tobacco Biological Effects and Biosynthesis, Beijing, China
| |
Collapse
|
3
|
del Casale A, Paolini M, Gentile G, Borro M, Zocchi C, Fiaschè F, Padovano A, Zoppi T, Modesti MN, De Luca O, Pomes LM, Brugnoli R, Ferracuti S, Girardi P, Pompili M, Simmaco M. Dopamine DRD2 and DRD3 Polymorphisms Involvement in Nicotine Dependence in Patients with Treatment-Resistant Mental Disorders. J Pers Med 2022; 12:jpm12040565. [PMID: 35455685 PMCID: PMC9033085 DOI: 10.3390/jpm12040565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 03/08/2022] [Accepted: 03/28/2022] [Indexed: 12/04/2022] Open
Abstract
Patients affected by mental disorders smoke more than the general population. The reasons behind this habit are genetic, environmental, etc. This study aims to investigate the correlations between some polymorphisms and the smoking habits and nicotine dependence in patients with psychiatric disorders. We recruited 88 patients with treatment-resistant mental disorders, including 35 with major depressive disorder, 43 with bipolar spectrum disorder, and 10 with schizophrenia spectrum disorder. We carried out a clinical and psychometric assessment on current smoking habits, years of smoking, number of daily cigarettes, and level of nicotine addiction. The patients performed a peripheral blood sample for DNA analyses of different polymorphisms. We searched for correlations between the measures of nicotine addiction and analysed genotypes. The expression of the T allele of the DRD2 rs1800497 and DRD3 rs6280 polymorphisms significantly correlated with a lower level of nicotine dependence and lower use of cigarettes. We did not find significant correlations between nicotine dependence and OPRM1 rs1799971, COMT rs4680 and rs4633 polymorphisms, CYP2A6 rs1801272 and rs28399433, or 5-HTTLPR genotype. Concluding, DRD2 rs1800497 and DRD3 rs6280 polymorphisms are involved in nicotine dependence and cigarette smoking habits in patients with treatment-resistant mental disorders
Collapse
Affiliation(s)
- Antonio del Casale
- Department of Dynamic and Clinical Psychology, and Health Studies, Faculty of Medicine and Psychology, Sapienza University, Via degli Apuli 2, 00185 Rome, Italy;
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Correspondence: ; Tel.: +39-0633777774
| | - Marco Paolini
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Giovanna Gentile
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
- Unit of Laboratory and Advanced Molecular Diagnostics, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy
| | - Marina Borro
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
- Unit of Laboratory and Advanced Molecular Diagnostics, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy
| | - Clarissa Zocchi
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Federica Fiaschè
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Alessio Padovano
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Teodolinda Zoppi
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Martina Nicole Modesti
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Ottavia De Luca
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
- Unit of Laboratory and Advanced Molecular Diagnostics, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy
| | - Leda Marina Pomes
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
- Unit of Laboratory and Advanced Molecular Diagnostics, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy
| | - Roberto Brugnoli
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Stefano Ferracuti
- Department of Human Neuroscience, Sapienza University, Viale dell’Università 30, 00185, Rome, Italy;
- Unit of Risk Management, ‘Sant’Andrea’University Hospital, Via di Grottarossa, 00189 Rome, Italy
| | - Paolo Girardi
- Department of Dynamic and Clinical Psychology, and Health Studies, Faculty of Medicine and Psychology, Sapienza University, Via degli Apuli 2, 00185 Rome, Italy;
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
| | - Maurizio Pompili
- Unit of Psychiatry, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy; (M.P.); (C.Z.); (F.F.); (A.P.); (T.Z.); (M.N.M.); (R.B.); (M.P.)
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
| | - Maurizio Simmaco
- Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Via di Grottarossa, 00189 Rome, Italy; (G.G.); (M.B.); (O.D.L.); (L.M.P.); (M.S.)
- Unit of Laboratory and Advanced Molecular Diagnostics, ‘Sant’Andrea’ University Hospital, Via di Grottarossa, 00189 Rome, Italy
| |
Collapse
|
4
|
Abstract
Tobacco smoking is a major determinant of preventable morbidity and mortality worldwide. More than a billion people smoke, and without major increases in cessation, at least half will die prematurely from tobacco-related complications. In addition, people who smoke have a significant reduction in their quality of life. Neurobiological findings have identified the mechanisms by which nicotine in tobacco affects the brain reward system and causes addiction. These brain changes contribute to the maintenance of nicotine or tobacco use despite knowledge of its negative consequences, a hallmark of addiction. Effective approaches to screen, prevent and treat tobacco use can be widely implemented to limit tobacco's effect on individuals and society. The effectiveness of psychosocial and pharmacological interventions in helping people quit smoking has been demonstrated. As the majority of people who smoke ultimately relapse, it is important to enhance the reach of available interventions and to continue to develop novel interventions. These efforts associated with innovative policy regulations (aimed at reducing nicotine content or eliminating tobacco products) have the potential to reduce the prevalence of tobacco and nicotine use and their enormous adverse impact on population health.
Collapse
Affiliation(s)
- Bernard Le Foll
- Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
- Departments of Family and Community Medicine, Psychiatry, Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
| | - Megan E Piper
- Department of Medicine, University of Wisconsin, Madison, WI, USA
- University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI, USA
| | - Christie D Fowler
- Department of Neurobiology and Behaviour, University of California Irvine, Irvine, CA, USA
| | - Serena Tonstad
- Section for Preventive Cardiology, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
| | - Laura Bierut
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
| | - Lin Lu
- Institute of Mental Health, Peking University Sixth Hospital, Peking University, Beijing, China
- National Institute on Drug Dependence, Peking University Health Science Center, Beijing, China
| | - Prabhat Jha
- Centre for Global Health Research, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada
| | - Wayne D Hall
- National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Queensland, Australia
- Queensland Alliance for Environmental Health Sciences, The University of Queensland, Woolloongabba, Queensland, Australia
| |
Collapse
|
5
|
Butler K, Le Foll B, Di Ciano P. The Role of Dopamine D3 Receptors in Tobacco Use Disorder: A Synthesis of the Preclinical and Clinical Literature. Curr Top Behav Neurosci 2023; 60:203-28. [PMID: 36173599 DOI: 10.1007/7854_2022_392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Tobacco smoking is a significant cause of preventable morbidity and mortality globally. Current pharmacological approaches to treat tobacco use disorder (TUD) are only partly effective and novel approaches are needed. Dopamine has a well-established role in substance use disorders, including TUD, and there has been a long-standing interest in developing agents that target the dopaminergic system to treat substance use disorders. Dopamine has 5 receptor subtypes (DRD1 to DRD5). Given the localization and safety profile of the dopamine receptor D3 (DRD3), it is of therapeutic potential for TUD. In this chapter, the preclinical and clinical literature investigating the role of DRD3 in processes relevant to TUD will be reviewed, including in nicotine reinforcement, drug reinstatement, conditioned stimuli and cue-reactivity, executive function, and withdrawal. Similarities and differences in findings from the animal and human work will be synthesized and findings will be discussed in relation to the therapeutic potential of targeting DRD3 in TUD.
Collapse
|
6
|
Mantey DS, Case KR, Chen B, Kelder S, Loukas A, Harrell MB. Subjective experiences at e-cigarette initiation: Implications for e-cigarette and dual/poly tobacco use among youth. Addict Behav 2021; 122:107028. [PMID: 34186298 PMCID: PMC8498802 DOI: 10.1016/j.addbeh.2021.107028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 06/15/2021] [Accepted: 06/19/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Subjective experiences (SEs) at initiation of cigarettes, cigars, and smokeless tobacco have been established as predictors of continued use. To date, less is known about the relationships between SEs at e-cigarette initiation and subsequent e-cigarette use behaviors. METHODS This study used data from Waves 1-6 of the Texas Adolescent Tobacco and Marketing Surveillance (TATAMS) system; a population-based rapid response study of adolescents in major metropolitan areas of Texas. Participants were adolescents who self-reported ever using e-cigarettes across all 6 waves (n = 1,104; N = 460,069). Factor analyses examined structure of SEs at e-cigarette initiation. Weighted, multilevel, multivariate regression models examined role of SEs at e-cigarette initiation on subsequent past 30-day e-cigarette use behaviors. RESULTS Factor analyses identified a positive (i.e., euphoria, relaxation) and a negative (i.e., dizziness, cough, nausea) domain of SEs. Positive SEs at e-cigarette initiation predicted 1.20 (95% CI: 1.02-1.42) greater odds of subsequent past 30-day e-cigarette use. Similarly, positive SEs at e-cigarette initiation predicted greater relative risk of dual/poly e-cigarette use, relative to non-use (RRR: 1.61; 95% CI: 1.24-2.10) and exclusive e-cigarette use (RRR: 1.68; 95% CI: 1.26-2.24). CONCLUSION This is the first study to observe longitudinal relationships between SEs at e-cigarette initiation and subsequent e-cigarette use behaviors. Findings highlight the importance of preventing initial e-cigarette use among adolescents.
Collapse
Affiliation(s)
- Dale S Mantey
- UT Health Science Center at Houston, UT Health, School of Public Health in Austin, 1616 Guadalupe, Suite 6.300, Austin, TX 78701, USA.
| | - Kathleen R Case
- UT Health San Antonio, Center for Research to Advance Community Health, 7411 John Smith Dr, Suite 1050, San Antonio, TX 78229, USA
| | - Baojiang Chen
- UT Health Science Center at Houston, UT Health, School of Public Health in Austin, 1616 Guadalupe, Suite 6.300, Austin, TX 78701, USA
| | - Steven Kelder
- UT Health Science Center at Houston, UT Health, School of Public Health in Austin, 1616 Guadalupe, Suite 6.300, Austin, TX 78701, USA
| | - Alexandra Loukas
- University of Texas at Austin, Department of Kinesiology & Health Education, University 2109 San Jacinto, D3700, Austin, TX 78712, USA
| | - Melissa B Harrell
- UT Health Science Center at Houston, UT Health, School of Public Health in Austin, 1616 Guadalupe, Suite 6.300, Austin, TX 78701, USA
| |
Collapse
|
7
|
Butler K, Chenoweth MJ, El-Boraie A, Giratallah H, Kowalczyk WJ, Heishman SJ, Tyndale RF, Le Foll B. Impact of CYP2A6 Activity on Nicotine Reinforcement and Cue-Reactivity in Daily Smokers. Nicotine Tob Res 2021; 23:1735-1743. [PMID: 33823003 DOI: 10.1093/ntr/ntab064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Accepted: 04/02/2021] [Indexed: 12/25/2022]
Abstract
INTRODUCTION Variation in CYP2A6, the primary enzyme responsible for nicotine metabolism, is associated with nicotine dependence, cigarette consumption, and abstinence outcomes in smokers. The impact of CYP2A6 activity on nicotine reinforcement and tobacco cue-reactivity, mechanisms that may contribute to these previous associations, has not been fully evaluated. AIMS AND METHODS CYP2A6 activity was indexed using 3 genetic approaches in 104 daily smokers completing forced-choice and cue-induced craving tasks assessing nicotine reinforcement and tobacco cue-reactivity, respectively. First, smokers were stratified by the presence or absence of reduced/loss-of-function CYP2A6 gene variants (normal vs. reduced metabolizers). As nicotine metabolite ratio (NMR) is a reliable biomarker of CYP2A6 activity, our second and third approaches used additional genetic variants identified in genome-wide association studies of NMR to create a weighted genetic risk score (wGRS) to stratify smokers (fast vs. slow metabolizers) and calculate a wGRS-derived NMR. RESULTS Controlling for race and sex, normal metabolizers (vs. reduced) selected a greater proportion of puffs from nicotine-containing cigarettes (vs. denicotinized) on the forced-choice task (p = .031). In confirmatory analyses, wGRS-based stratification (fast vs. slow metabolizers) produced similar findings. Additionally, wGRS-derived NMR, which correlated with actual NMR assessed in a subset of participants (n = 55), was positively associated with the proportion of puffs from nicotine-containing cigarettes controlling for race and sex (p = .015). None of the CYP2A6 indices were associated with tobacco cue-reactivity in minimally deprived smokers. CONCLUSIONS Findings suggest increased nicotine reinforcement is exhibited by smokers with high CYP2A6 activity, which may contribute to heavier smoking and poorer cessation outcomes previously reported in faster metabolizers. IMPLICATIONS CYP2A6 activity is a key determinant of smoking behavior and outcomes. Therefore, these findings support the targeting of CYP2A6 activity, either therapeutically or as a clinically relevant biomarker in a precision medicine approach, for tobacco use disorder treatment.
Collapse
Affiliation(s)
- Kevin Butler
- Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada
| | - Meghan J Chenoweth
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.,Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
| | - Ahmed El-Boraie
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.,Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
| | - Haidy Giratallah
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.,Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
| | - William J Kowalczyk
- National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA.,Department of Psychology, Hartwick College, Oneonta, NY, USA
| | - Stephen J Heishman
- National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA
| | - Rachel F Tyndale
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.,Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Bernard Le Foll
- Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada.,Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.,Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada.,Acute Care Program, Centre for Addiction and Mental Health, Toronto, ON, Canada.,Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.,Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
8
|
Abstract
Relapse is common amongst smokers attempting to quit and tobacco cue-induced craving is an important relapse mechanism. Preclinical studies commonly use cue-induced reinstatement of nicotine seeking to investigate relapse neurobiology. Previous research suggests dependence severity and nicotine intake history affect smoking resumption and cue-induced reinstatement of nicotine seeking. However, behavioural data may be interpreted in terms of nicotine reinforcement. This translational study investigated if individual differences in objectively assessed nicotine reinforcement strength were associated with cue-reactivity in both rats and human smokers, which to our knowledge has not been investigated before. Rats (n = 16) were trained to self-administer nicotine and were tested on a progressive ratio schedule of nicotine reinforcement, to assess reinforcer strength, and on a test of cue-induced reinstatement of nicotine seeking. Nicotine reinforcement strength was assessed in human smokers (n = 104) using a forced choice task (nicotine containing vs. denicotinised cigarettes) and self-reported cue-induced craving was assessed following exposure to smoking and neutral cues. Responding for nicotine under progressive ratio was strongly positively correlated with cue-induced reinstatement of nicotine seeking in rats. Nicotine choices in human smokers were significantly associated with cue-induced craving controlling for dependence severity, years of smoking, and urge to smoke following neutral cues. Findings suggest nicotine reinforcement strength is associated with both types of cue-induced behaviour, implying some translational commonality between cue-induced craving in human smokers and cue-induced reinstatement of nicotine seeking in rats. Findings are discussed in relation to clinical implications and whether these laboratory tasks assess drug 'wanting'.
Collapse
Affiliation(s)
- Kevin Butler
- Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada
| | - Benoît Forget
- Department of Neuroscience, Pasteur Institute, Paris, France
| | - Stephen J Heishman
- National Institute on Drug Abuse, Intramural Research Program, Baltimore, USA
| | - Bernard Le Foll
- Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada
| |
Collapse
|
9
|
He Q, Wu J, Wang X, Luo F, Yan K, Yu W, Mo Z, Jiang X. Exercise intervention can reduce the degree of drug dependence of patients with amphetamines/addiction by improving dopamine level and immunity and reducing negative emotions. Am J Transl Res 2021; 13:1779-1788. [PMID: 33841702 PMCID: PMC8014419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Accepted: 08/26/2020] [Indexed: 06/12/2023]
Abstract
OBJECTIVE Exercise intervention can reduce drug dependence of patients with amphetamines addiction by improving dopamine level and immunity, and reducing negative emotions. METHODS Altogether 90 male patients with amphetamines addiction from March 2018 to June 2019 were selected and grouped. The routine rehabilitation group (RG) (30 cases) was given conventional rehabilitation treatment, while group 1 (30 cases) was given conventional rehabilitation treatment+aerobic exercise for 1 hour. Group 2 (30 cases) received routine rehabilitation+aerobic exercise+strength training for 1 hour. Before and after exercise intervention, the three groups were tested for psychological state with self-rating depression scale (SDS). Visual analogue scale (VAS) was used to evaluate the drug craving. Positive and negative syndrome scale (PANSS) and quality of life scale for drug addiction (QOL-DA) were used to detect the mental status and QOL. The immune function, high sensitivity C-reactive protein (hs-CRP) and dopamine (DA) levels were detected. RESULTS After intervention, the SDS, VAS and PANSS of group 1 and group 2 weresignificantly better than those of RG, while the improvement of scores of group 2 wassignificantly better than that of group 1 (P < 0.05). hs-CRP in group 1 and group 2 were significantly lower than those in RG, while hs-CRP in group 2 weresignificantly lower than those in group 1 (P < 0.05). IgA, IgG and DA in group 1 and group 2 weresignificantly higher than those in RG, and IgA, IgG and DA in group 2 weresignificantly higher than those in group 1 (P < 0.05). QOL-DA in group 1 and 2 weresignificantly higher than those of RG, and the improvement of scores of group 2 wassignificantly better than that of group 1 (P < 0.05). CONCLUSION Psychological status, drug craving, immune function, DA and QOL of patients with amphetamines addiction have been improved after exercise intervention.
Collapse
Affiliation(s)
- Qinghua He
- School of Physical Education and Health Science, Guangxi University for NationalitiesNanning 530006, Guangxi, China
| | - Jingqiong Wu
- Department of Physical Education, Guangxi Medical UniversityNanning 530021, Guangxi, China
| | - Xin Wang
- The Sixth Compulsory Isolation and Rehabilitation Center of GuangxiBeihai 536000, Guangxi Province, China
| | - Fuxuan Luo
- The Sixth Compulsory Isolation and Rehabilitation Center of GuangxiBeihai 536000, Guangxi Province, China
| | - Kaihui Yan
- The Sixth Compulsory Isolation and Rehabilitation Center of GuangxiBeihai 536000, Guangxi Province, China
| | - Wenjun Yu
- School of Physical Education and Health Science, Guangxi University for NationalitiesNanning 530006, Guangxi, China
| | - Zaimei Mo
- School of Physical Education and Health Science, Guangxi University for NationalitiesNanning 530006, Guangxi, China
| | - Xinping Jiang
- School of Physical Education and Health Science, Guangxi University for NationalitiesNanning 530006, Guangxi, China
| |
Collapse
|
10
|
Abstract
Cigarette use is the leading cause of preventable death in the United
States. Despite the well documented dangers of smoking, nearly 20% of
adults report regular use of tobacco. A majority desire to discontinue
but the long-term cessation success rate remains near 4%. One
challenge to reducing the prevalence of tobacco use is an incomplete
understanding of the individual correlates that reinforce continued
use. Evidence from research on nicotine and tobacco suggests that
Tobacco Use Disorder is a complex, and multifactorial condition.
Personality traits, comorbidities, habits and lifestyle, genetics,
socioeconomic status, and mental and physical health all contribute to
the risk for dependence and to the likelihood of quitting. This
perspective review provides an overview of some common factors that
contribute to liability risk for Tobacco Use Disorder and a framework
for assessing individual tobacco users. The framework includes 5 areas
that research suggests contribute to continued tobacco use: nicotine
addiction, psychological influences, behavioral dependencies,
neurobiological factors, and social reinforcement. Nicotine addiction
includes drug-seeking behavior and the role of withdrawal avoidance.
Psychological and emotional states contribute to a perceived reliance
on tobacco. Behavioral dependence is reinforced by associative and
non-associative learning mechanisms. Neurobiological factors include
genetic variables, variations in neurotransmitters and receptors,
pharmacogenetics, and interaction between psychiatric illnesses and
nicotine use and dependence. Finally, social reinforcement of smoking
behavior is explained by a network phenomenon and consistent visual
cues to smoke. A comprehensive assessment of individual tobacco users
will help better determine appropriate treatment options to achieve
improved efficacy and outcomes.
Collapse
|
11
|
Chukwueke CC, Kowalczyk WJ, Gendy M, Taylor R, Tyndale RF, Le Foll B, Heishman SJ. The CB1R rs2023239 receptor gene variant significantly affects the reinforcing effects of nicotine, but not cue reactivity, in human smokers. Brain Behav 2021; 11:e01982. [PMID: 33369277 PMCID: PMC7882168 DOI: 10.1002/brb3.1982] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 11/09/2020] [Accepted: 11/14/2020] [Indexed: 12/28/2022] Open
Abstract
INTRODUCTION The cannabinoid CB1 receptor (CB1R) has been shown in preclinical studies to be involved in nicotine reinforcement and relapse-like behavior. The common single nucleotide polymorphism (SNP) rs2023239 may code for an alternative CB1R protein, alter CB1R expression, and be involved in nicotine dependence. To date, no study has explored the relationship between this SNP in CB1R and specific phenotypes of nicotine dependence. METHODS The current study investigated the influence of CB1R rs2023239 in nicotine reinforcement and craving in regular cigarette smokers. Current smokers (n = 104, cigarettes per day ≥ 10) were genetically grouped (C allele group vs. No C allele group) and underwent laboratory measures of nicotine reinforcement and smoking cue-elicited craving. Nicotine reinforcement was assessed using a forced choice paradigm, while a cue-reactivity procedure measured cue-elicited craving. RESULTS These results show that smokers with the C allele variant (CC + CT genotypes) experienced a lower nicotine reinforcement effect compared to those without the C allele (TT genotype). These results were similar in both our subjective and behavioral reinforcement measures, though the subjective effects did not withstand controlling for race. There was no difference between genotype groups with respect to cue-elicited craving, suggesting a lack of influence in cue reactivity. CONCLUSION Taken together, these results suggest that the variation in the CB1R (i.e., rs2023239 SNP) may play a larger role in nicotine reinforcement compared to cue reactivity. This work provides impetus to further understand the physiological mechanisms that explain how CB1Rs influence nicotine dependence phenotypes.
Collapse
Affiliation(s)
- Chidera C Chukwueke
- Translational Addiction Research Laboratory, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.,Department of Pharmacology, University of Toronto, Toronto, ON, Canada
| | - William J Kowalczyk
- Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA.,Department of Psychology, Hartwick College, Oneonta, NY, USA
| | - Marie Gendy
- Translational Addiction Research Laboratory, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.,Department of Pharmacology, University of Toronto, Toronto, ON, Canada
| | - Richard Taylor
- Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA
| | - Rachel F Tyndale
- Department of Pharmacology, University of Toronto, Toronto, ON, Canada.,CAMH, Campbell Family Mental Health Research Institute, Toronto, ON, Canada.,Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Bernard Le Foll
- Translational Addiction Research Laboratory, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.,Department of Pharmacology, University of Toronto, Toronto, ON, Canada.,CAMH, Campbell Family Mental Health Research Institute, Toronto, ON, Canada.,Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.,Acute Care Program, CAMH, Toronto, ON, Canada.,Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.,Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.,Centre for Addiction and Mental Health, Institute for Mental Health Policy Research, Toronto, ON, Canada
| | - Stephen J Heishman
- Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA
| |
Collapse
|